AET BioTech is your preferred partner for the collaborative development of biosimilars. Built on a 50 year success story of the oldest player in the field of generics, the AET Group (Alfred E. Tiefenbacher GmbH & Co. KG), AET BioTech benefits from exceptional experience in scientific, legal and technical fields and leverages its specific know-how in joint development programs, taking biosimilars from concept to worldwide registration and supplying to leading pharmaceutical brands.
Honoring the specific challenges inherent in the development of biologics on the one hand, and the exceptional economic opportunities of providing biological medications with the highest standards of quality at reasonable prices on the other hand, AET BioTech’s business model offers selected partners opportunities to safeguard access to regional distribution rights by early investment into a shared risk development model.
AET BioTech welcomes parties interested in collaborating on any area of the business to make contact › here.
AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology
European Medicines Agency to accept biosimilar reference medicines sourced outside European Economic Area
The European Medicines Agency has updated its guidance for pharmaceutical companies on biosimilar medicines to reflect the European Commission's confirmation that it
Following the Biologics Price Competition and Innovation act of 2009, the BsUFA enables payments to the FDA to support reviews of biosimilar drug applications in the USA. The